Monte Rosa Therapeutics Inc Stock

$4.06

7.94% today

Nasdaq, Apr 03, 06:50 pm CET

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Monte Rosa Therapeutics Inc Stock price

$4.41

-16.77 79.18% 5Y

Nasdaq, Closing price Wed, Apr 02 2025

-0.02 0.45%

ISIN

US61225M1027

Symbol

GLUE

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$271.26m
Enterprise Value	$-58.17m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	-0.77
P/S ratio (TTM) P/S ratio	3.59
P/B ratio (TTM) P/B ratio	1.22
Revenue (TTM) Revenue	$75.62m
EBIT (operating result TTM) EBIT	$-81.11m
Free Cash Flow (TTM) Free Cash Flow	$38.01m
Cash position	$372.15m
EPS (TTM) EPS	$-1.03
P/E forward	negative
P/S forward	5.78
EV/Sales forward	negative
Short interest	20.87%

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Get Started for Free Today

Monte Rosa Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Monte Rosa Therapeutics Inc forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Monte Rosa Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	76 76	- 100%
- Direct Costs	8.12 8.12	31% 31% 11%
Gross Profit	68 68	1,185% 1,185% 89%
- Selling and Administrative Expenses	27 27	5% 5% 36%
- Research and Development Expense	113 113	8% 8% 150%
EBITDA	-73 -73	47% 47% -97%
- Depreciation and Amortization	8.12 8.12	31% 31% 11%
EBIT (Operating Income) EBIT	-81 -81	43% 43% -107%
Net Profit	-73 -73	46% 46% -96%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Monte Rosa Therapeutics Inc Stock News

Neutral

Seeking Alpha

●

14 days ago

Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Partic...

Neutral

GlobeNewsWire

●

14 days ago

Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs

Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated disease...

Neutral

GlobeNewsWire

●

23 days ago

Monte Rosa Therapeutics to Present Pipeline Update and Release Fourth Quarter and Full Year 2024 Financial Results on March 20, 2025

Company to present clinical results from Phase 1 SAD/MAD study of VAV1-directed molecular glue degrader MRT-6160 and Phase 1/2 study of MRT-2359 in MYC-driven solid tumors Conference call and webcast planned for 8 a.m. ET on March 20, 2025 BOSTON, March 11, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular gl...

More Monte Rosa Therapeutics Inc News

Company Profile

Monte Rosa Therapeutics, Inc. operates as a biotechnology company focused on developing precision medicines. The company was founded on November 21, 2019 and is headquartered in Boston, MA.

Head office	United States
CEO	Markus Warmuth
Employees	134
Founded	2019
Website	www.monterosatx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now